Suchergebnisse - "Sehouli, Jalid"

PubPharm (38)

1

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer : The Phase III DUO-E Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Westin, S. | Moore, K. | Chon, H. | +128

2

AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer : a multicenter randomized phase III trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2023

von Heitz, F. | Marth, C. | Henry, S. | +15

3

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

enthalten in: Gynecologic oncology | 2023

von Herzog, T. | Pignata, S. | Ghamande, S. | +21

4

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer : AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Pfisterer, J. | Joly, F. | Kristensen, G. | +27

CommentIn: J Clin Oncol. 2023 Apr 1;41(10):1952-1953. - PMID 36763910

5

Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer

enthalten in: Gynecologic oncology | 2022

von Rubinstein, M. | Shen, S. | Monk, B. | +5

6

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

enthalten in: JCI insight | 2022

von Huehnchen, P. | Schinke, C. | Bangemann, N. | +13

7

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer : Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Moore, K. | Bookman, M. | Sehouli, J. | +25

CommentIn: J Clin Oncol. 2021 Jun 10;39(17):1833-1838. - PMID 33891471

8

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2020

von Harter, P. | Pautier, P. | Van Nieuwenhuysen, E. | +15

9

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors : The ALIENOR/ENGOT-ov7 Randomized Clinical Trial

enthalten in: JAMA oncology | 2020

von Ray-Coquard, I. | Harter, P. | Lorusso, D. | +17

10

MILO/ENGOT-ov11 : Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Monk, B. | Grisham, R. | Banerjee, S. | +27

CommentIn: J Clin Oncol. 2020 Nov 10;38(32):3731-3734. - PMID 32897828